IONS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 16.72%. Ionis Pharmaceuticals's return on equity of -103.27% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 125.56%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.77 which suggests that it could grow by 73.14%. Given that Ionis Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Ionis Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Ionis Pharmaceuticals has a beta of 0.287, which suggesting that the stock is 71.35% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 25.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 5.41x versus 3.89x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 39.44%. Ionis Pharmaceuticals's return on equity of -103.27% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 125.56%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 58.29%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.287, which suggesting that the stock is 71.35% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 16.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 5.41x versus 5.44x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Dynavax Technologies has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 9.79%. Ionis Pharmaceuticals's return on equity of -103.27% beat Dynavax Technologies's return on equity of 4.32%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 125.56%. On the other hand Dynavax Technologies has an analysts' consensus of $24.75 which suggests that it could grow by 110.64%. Given that Ionis Pharmaceuticals has higher upside potential than Dynavax Technologies, analysts believe Ionis Pharmaceuticals is more attractive than Dynavax Technologies.

Ionis Pharmaceuticals has a beta of 0.287, which suggesting that the stock is 71.35% less volatile than S&P 500. In comparison Dynavax Technologies has a beta of 1.265, suggesting its more volatile than the S&P 500 by 26.451%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Dynavax Technologies pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are larger than Dynavax Technologies quarterly revenues of $72M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Dynavax Technologies's net income of $7.1M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Dynavax Technologies's PE ratio is 65.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 5.41x versus 6.06x for Dynavax Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 25.08%. Ionis Pharmaceuticals's return on equity of -103.27% beat Zoetis's return on equity of 49.71%.

Ionis Pharmaceuticals has a consensus price target of $57.54, signalling upside risk potential of 125.56%. On the other hand Zoetis has an analysts' consensus of $199.87 which suggests that it could grow by 38.4%. Given that Ionis Pharmaceuticals has higher upside potential than Zoetis, analysts believe Ionis Pharmaceuticals is more attractive than Zoetis.

Ionis Pharmaceuticals has a beta of 0.287, which suggesting that the stock is 71.35% less volatile than S&P 500. In comparison Zoetis has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.51%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.24% to investors and pays a quarterly dividend of $0.50 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Zoetis quarterly revenues of $2.3B. Ionis Pharmaceuticals's net income of -$104.3M is lower than Zoetis's net income of $581M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Zoetis's PE ratio is 26.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 5.41x versus 7.10x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.